Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19)

Clinical Infectious Diseases

Volumn 71, Issue 15, 2020, Pages 799-806

  Xu, Kaijin ^a   Chen, Yanfei ^a   Yuan, Jing ^b   Yi, Ping ^a   Ding, Cheng ^a   Wu, Wenrui ^a   Li, Yongtao ^a   Ni, Qin ^a   Zou, Rongrong ^b   Li, Xiaohe ^b   Xu, Min ^a   Zhang, Ying ^a   Zhao, Hong ^a   Zhang, Xuan ^a   Yu, Liang ^a   Su, Junwei ^a   Lang, Guanjing ^a   Liu, Jun ^a   Wu, Xiaoxin ^a   Guo, Yongzheng ^a   Tao, Jingjing ^a   Shi, Ding ^a   Yu, Ling ^a   Cao, Qing ^a   Ruan, Bing ^a   Liu, Lei ^b   Wang, Zhaoqin ^b   Xu, Yan ^a   Liu, Yingxia ^b   Sheng, Jifang ^a   Li, Lanjuan ^a   more..

^a ZHEJIANG UNIVERSITY   (China)

^b SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

Author keywords

Coronavirus; COVID 19; Risk factors; SARS COV 2; Viral shedding

Indexed keywords

CORTICOSTEROID; VIRUS RNA;

ADULT; ARTICLE; BODY TEMPERATURE; CHINA; COHORT ANALYSIS; CORONAVIRUS DISEASE 2019; CORTICOSTEROID THERAPY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; INVASIVE VENTILATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SENESCENCE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS SHEDDING; ADVERSE EVENT; ARTIFICIAL VENTILATION; BETACORONAVIRUS; CLINICAL TRIAL; CORONAVIRUS INFECTION; DISEASE EXACERBATION; FEMALE; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PANDEMIC; PATHOGENICITY; SEX FACTOR; TIME FACTOR; TIME TO TREATMENT; VIROLOGY; VIRUS PNEUMONIA;

ADULT; BETACORONAVIRUS; CHINA; COHORT STUDIES; CORONAVIRUS INFECTIONS; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SEX FACTORS; TIME FACTORS; TIME-TO-TREATMENT; VIRUS SHEDDING;

EID: 85083177263     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciaa351     Document Type: Article

References (30)

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507-13.
2. World Health Organization. WHO 2019 nCoV situation report. Available at: https://covid19.who.int. Accessed 14 April 2020.
3. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368:m606.
4. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:145-51.
5. Clinical management of 2019 nCoV guidelines by National Health Commission of the People Republic of China. Available at: http://www.nhc.gov.cn/yzygj/s7652m/202002/54e1ad5c2aac45c19eb541799bf637e9.shtml. Accessed 14 April 2020.
6. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382:1177-9.
7. Tsang TK, Cowling BJ, Fang VJ, et al. Influenza A virus shedding and infectivity in households. J Infect Dis 2015; 212:1420-8.
8. Peiris JS, Chu CM, Cheng VC, et al; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767-72.
9. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020; 9:386-9.
10. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 14 April 2020.
11. Leong HN, Earnest A, Lim HH, et al. SARS in Singapore-predictors of disease severity. Ann Acad Med Singapore 2006; 35:326-31.
12. Alghamdi IG, Hussain II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. Int J Gen Med 2014; 7:417-23.
13. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 2015; 14:309-21.
14. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005; 11:411-23.
15. Kadioglu A, Cuppone AM, Trappetti C, et al. Sex-based differences in susceptibility to respiratory and systemic pneumococcal disease in mice. J Infect Dis 2011; 204:1971-9.
16. Li W, Zhang C, Sui J, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005; 24:1634-43.
17. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020.
18. Gupte M, Thatcher SE, Boustany-Kari CM, et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler Thromb Vasc Biol 2012; 32:1392-9.
19. Clotet-Freixas S, Soler MJ, Palau V, et al. Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy. Lab Invest 2018; 98:1237-49.
20. Chu CM, Cheng VC, Hung IF, et al; HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252-6.
21. Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferonβ1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212:1904-13.
22. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020.
23. Wang Y, Guo Q, Yan Z, et al; CAP-China Network. Factors associated with prolonged viral shedding in patients with avian influenza A(H7N9) virus infection. J Infect Dis 2018; 217:1708-17.
24. Arabi YM, Mandourah Y, Al-Hameed F, et al; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018; 197:757-67.
25. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31:304-9.
26. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7.
27. van Riel D, Munster VJ, de Wit E, et al. H5N1 virus attachment to lower respiratory tract. Science 2006; 312:399.
28. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature 2006; 440:435-6.
29. Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 2009; 49:279-90.
30. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 2016; 6:25359.